» Articles » PMID: 15388580

Proteolytic Inactivation of ADAMTS13 by Thrombin and Plasmin

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Sep 25
PMID 15388580
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

The multimeric size and the function of circulating von Willebrand factor are modulated via its proteolytic cleavage by the plasma metalloproteinase, ADAMTS13. It is unclear how ADAMTS13 activity is regulated within the vascular system. In the absence of a regulatory mechanism, ADAMTS13 activity might compromise platelet adhesion at sites of vascular injury. We hypothesized that at sites of vascular injury, ADAMTS13 activity could be regulated locally by coagulation proteinases. Initiation of coagulation in human plasma resulted in the disappearance of added full-length recombinant ADAMTS13. This loss was inhibited by hirudin. Using purified proteins, we showed that ADAMTS13 is proteolyzed at several cleavage sites by thrombin in a time- and concentration-dependent manner. Furthermore, this proteolysis ablated ADAMTS13 activity against purified von Willebrand factor. Preincubation of thrombin with soluble thrombomodulin, but not heparin, inhibited the proteolysis of ADAMTS13, suggesting the involvement of thrombin exosite I (and not exosite II) in ADAMTS13 recognition. Plasmin also cleaved ADAMTS13 into similar fragments, resulting in the loss of ADAMTS13 activity. This study demonstrates the susceptibility of ADAMTS13 to proteolytic inactivation and suggests possible roles for thrombin and plasmin at sites of vascular injury.

Citing Articles

Role of von Willebrand factor, platelets, and aberrant flow in the initiation of venous thrombosis.

Mereweather L, Harwood D, Ahnstrom J, van Batenburg-Sherwood J, Salles-Crawley I, Crawley J Sci Adv. 2025; 11(6):eadr5250.

PMID: 39908367 PMC: 11797557. DOI: 10.1126/sciadv.adr5250.


ADAMTS13 Improves Endothelial Function and Reduces Inflammation in Diabetic Retinopathy.

Abu El-Asrar A, Nawaz M, Ahmad A, Siddiquei M, Allegaert E, Adyns L Cells. 2025; 14(2).

PMID: 39851513 PMC: 11764296. DOI: 10.3390/cells14020085.


Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13.

Madarati H, DeYoung V, Singh K, Sparring T, Kwong A, Fredenburgh J Sci Rep. 2024; 14(1):9073.

PMID: 38643218 PMC: 11032339. DOI: 10.1038/s41598-024-59672-6.


Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study.

Papadogeorgou P, Valsami S, Boutsikou M, Pergantou E, Mantzou A, Papassotiriou I Medicina (Kaunas). 2024; 60(2).

PMID: 38399555 PMC: 10890703. DOI: 10.3390/medicina60020268.


ADAMTS13 regulates angiogenic markers via Ephrin/Eph signaling in human mesenchymal stem cells under serum-deprivation stress.

Dutta Gupta S, Ta M Sci Rep. 2024; 14(1):560.

PMID: 38177376 PMC: 10766954. DOI: 10.1038/s41598-023-51079-z.